Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search


Solbec Announces Grant Of Australian Patent


· Solbec advises the granting of Australian patent, number 779512, entitled “Medicinal compositions and their method of preparation”.

Perth, Australia. 14 June 2005. Solbec Pharmaceuticals (ASX: SBP) advises that the Australian patent, number 779512, entitled “Medicinal compositions and their method of preparation” has been granted. This provides additional protection to the Company’s lead compound Coramsine™. The term of the patent runs until April 2020.

The “Medicinal compositions” patent covers aspects of the manufacturing, purification process and formulation of the active pharmaceutical ingredients of Coramsine™. It is the second Coramsine™ related patent application to be granted. International cases of the application are ongoing.

Coramsine™ is now covered by seven families of patents / patent applications that are expected to provide protection until 2023. They extend to clinical application, extraction and purification, the cell receptor involved in Coramsine™ selectivity, Coramsine’s™ effect on Interleukin-6 production, and Coramsine™ combination therapy.

Background Information

Solbec Pharmaceuticals Ltd identifies naturally-occurring compounds with potential in the development of better therapies for debilitating conditions and life-threatening diseases. The company is currently progressing its key project, Coramsine™, through Phase I/IIA clinical trials for the treatment of advanced solid tumours, and as a topical treatment for psoriasis. Solbec's two proprietary ingredients in Coramsine™ were isolated from the fruit of a plant known as the Devil’s Apple (Solanum linnaeanum). They show activity against some cancers and cause potentially therapeutic changes to the immune system. In addition to human health, Coramsine™ has potential application in the areas of animal health and diagnostics. Solbec’s business strategy is to partner or out-license Coramsine™ for the final stages of pre-commercial development and marketing.

© Scoop Media

Business Headlines | Sci-Tech Headlines


Onetai Station: Overseas Investment Office Puts Ceol & Muir On Notice

The Overseas Investment Office (OIO) has issued a formal warning to Ceol & Muir and its owners, Argentinian brothers Rafael and Federico Grozovsky, for failing to provide complete and accurate information when they applied to buy Onetai Station in 2013. More>>


Tomorrow, The UN: Feds President Takes Reins At World Farming Body

Federated Farmers president Dr William Rolleston has been appointed acting president of the World Farmers’ Organisation (WFO) at a meeting in Geneva overnight. More>>


I Sing The Highway Electric: Charge Net NZ To Connect New Zealand

BMW is turning Middle Earth electric after today announcing a substantial contribution to the charging network Charge Net NZ. This landmark partnership will enable Kiwis to drive their electric vehicles (EVs) right across New Zealand through the installation of a fast charging highway stretching from Kaitaia to Invercargill. More>>


Watch This Space: Mahia Rocket Lab Launch Site Officially Opened

Economic Development Minster Steven Joyce today opened New Zealand’s first orbital launch site, Rocket Lab Launch Complex 1, on the Mahia Peninsula on the North Island’s east coast. More>>


Marketing Rocks!
Ig Nobel Award Winners Assess The Personality Of Rocks

A Massey University marketing lecturer has received the 2016 Ig Nobel Prize for economics for a research project that asked university students to describe the “brand personalities” of three rocks. More>>


Nurofen Promotion: Reckitt Benckiser To Plead Guilty To Misleading Ads

Reckitt Benckiser (New Zealand) intends to plead guilty to charges of misleading consumers over the way it promoted a range of Nurofen products, the Commerce Commission says. More>>


Get More From Scoop

Search Scoop  
Powered by Vodafone
NZ independent news